JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

MRI of hemangioblastoma in the conus medullaris.

Hemangioblastoma of the conus medullaris with MRI has not been reported before. A 75-year-old man had a history of falling due to weakness of his left lower limb. MRI revealed a well-defined oval mass in the conus medullaris. The tumor had an isointense signal relative to spinal cord on T1-weighted images, hyperintense signal areas intermixed with punctate spots of hypointensity on T2-weighted images, and heterogeneous obvious enhancement on gadolinium-enhanced T1-weighted images. Associated abnormally tortuous vessels were noted in the dura proximal to the tumor. Histological findings were compatible with the diagnosis of hemangioblastoma. Hemangioblastoma should be included in the differential diagnosis in patients with an enhancing tumor and adjacent engorged vessels of the spinal cord.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app